Is there a significant difference in the use of short-acting Î2 2 -agonists between the moderate and severe airway limitation groups?
1. What is the frequency and percentage of COPD patients in the severe airway limitation group recruited for the Eckerblad et al. (2014) study?
2. What proportion of the total sample is retired? What percentage of the total sample is ill?
3. What is the study’s total sample size? What was the frequency and percentage of the total sample that was still in use? Display your calculations and round your answer to the nearest whole percentage point.
4. What is the total percentage of the sample with a smoking history, whether current or former smokers? Is it clinically significant for study participants to have a smoking history? Give a reason for your answer.
5. What do pack years of smoking entail? Is there a significant difference in pack years of smoking between the moderate and severe airway limitation groups? Give a reason for your answer.
6. What were the top four psychological symptoms reported by this group of COPD patients? What percentage of these people had these symptoms? Was there a significant difference in psychological symptoms between the moderate and severe airway limitation groups?
7. What percentage of the total sample used short-acting Î2 2 -agonists, and how frequently? Display your calculations and round to the nearest whole percentage point.
8. Is there a significant difference in the use of short-acting Î2 2 -agonists between the moderate and severe airway limitation groups? Give a reason for your answer.
9. Did the percentage of COPD patients with moderate to severe airway limitation who used short-acting Î2 2 -agonists match your expectations? Give a rationale and supporting documentation for your answer.
10. Can these findings be used in practice? Give a reason for your answer?